SG11202101904UA - Spd-1 variant - fc fusion proteins - Google Patents

Spd-1 variant - fc fusion proteins

Info

Publication number
SG11202101904UA
SG11202101904UA SG11202101904UA SG11202101904UA SG11202101904UA SG 11202101904U A SG11202101904U A SG 11202101904UA SG 11202101904U A SG11202101904U A SG 11202101904UA SG 11202101904U A SG11202101904U A SG 11202101904UA SG 11202101904U A SG11202101904U A SG 11202101904UA
Authority
SG
Singapore
Prior art keywords
spd
variant
fusion proteins
fusion
proteins
Prior art date
Application number
SG11202101904UA
Other languages
English (en)
Inventor
Amato J Giaccia
Todd A Aguilera
Mihalis S Kariolis
Yu Miao
Kaushik Thakkar
Xin Eric Zhang
Original Assignee
Univ Leland Stanford Junior
Akso Biopharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior, Akso Biopharmaceutical Inc filed Critical Univ Leland Stanford Junior
Publication of SG11202101904UA publication Critical patent/SG11202101904UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11202101904UA 2018-09-14 2019-09-12 Spd-1 variant - fc fusion proteins SG11202101904UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862731488P 2018-09-14 2018-09-14
US201962888320P 2019-08-16 2019-08-16
PCT/US2019/050742 WO2020056085A1 (en) 2018-09-14 2019-09-12 Spd-1 variant - fc fusion proteins

Publications (1)

Publication Number Publication Date
SG11202101904UA true SG11202101904UA (en) 2021-04-29

Family

ID=68211179

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202101904UA SG11202101904UA (en) 2018-09-14 2019-09-12 Spd-1 variant - fc fusion proteins

Country Status (11)

Country Link
US (2) US11498955B2 (https=)
EP (1) EP3850003A1 (https=)
JP (1) JP2021535761A (https=)
KR (1) KR20210058902A (https=)
CN (1) CN112969710A (https=)
AU (1) AU2019338416A1 (https=)
CA (1) CA3109983A1 (https=)
NZ (1) NZ774126A (https=)
SG (1) SG11202101904UA (https=)
TW (2) TW202348622A (https=)
WO (1) WO2020056085A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016164428A1 (en) * 2015-04-06 2016-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway
EP3991741A1 (en) * 2020-11-02 2022-05-04 Klinikum rechts der Isar der Technischen Universität München An immune checkpoint-modulating vsv-ndv hybrid virus for oncolytic virus immonotherapy of cancer
US20230414660A1 (en) * 2020-11-13 2023-12-28 Ludwig Institute For Cancer Research Ltd Pd-1 decoy variants for immunotherapy
WO2022137186A1 (en) 2020-12-23 2022-06-30 Crispr Therapeutics Ag Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor
KR102618718B1 (ko) * 2021-01-11 2023-12-29 주식회사 유틸렉스 항-4-1bb 항체 및 pd-1 단백질 또는 이의 단편을 포함하는 이중특이적 에피토프 결합 단백질 및 이의 용도
WO2022167729A1 (en) * 2021-02-04 2022-08-11 Helsingin Yliopisto A cross-hybrid fc-fusion polypeptide targeting pd-l1 and methods and uses related thereto
US20240141014A1 (en) * 2021-03-03 2024-05-02 Shattuck Labs, Inc. Mutant pd-1 extracellular domains
AR125851A1 (es) 2021-05-12 2023-08-16 Crispr Therapeutics Ag Células inmunes modificadas genéticamente que se focalizan en cd70 para su uso en el tratamiento de neoplasias malignas hematopoyéticas
CA3220027A1 (en) * 2021-05-28 2022-12-01 Amato J. Giaccia Bispecific fc fusion proteins with spd-1 and il-15
WO2023048518A1 (ko) * 2021-09-24 2023-03-30 바이오엔시스템스 주식회사 Pd-1 및 il-15를 포함하는 융합단백질 이량체 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110034373A1 (en) * 2007-08-03 2011-02-10 Eli Lilly And Company Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
CN107090029B (zh) * 2010-11-11 2021-07-13 港大科桥有限公司 可溶性 pd-1变体、融合构建体及其用途
US20150368316A1 (en) * 2013-02-07 2015-12-24 Albert Einstein College Of Medicine Of Yeshiva University A selective high-affinity immune stimulatory reagent and uses thereof
PT3177640T (pt) * 2014-08-08 2020-08-31 Univ Leland Stanford Junior Agentes pd-1 de alta afinidade e métodos de utilização
WO2016023001A1 (en) * 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Multispecific high affinity pd-1 agents and methods of use
WO2016164428A1 (en) * 2015-04-06 2016-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway
CN115925878A (zh) * 2015-06-05 2023-04-07 艾比欧公司 用于治疗纤维化的内皮抑素片段和变体
ES2924402T3 (es) * 2015-10-02 2022-10-06 Symphogen As Anticuerpos anti-PD-1 y composiciones
WO2017123548A1 (en) 2016-01-14 2017-07-20 Seattle Children's Hospital (dba Seattle Children's Research Institute) Tumor-specific ifna secretion by car t-cells to reprogram the solid tumor microenvironment
US20190358263A1 (en) * 2016-12-07 2019-11-28 Oslo Universitetssykehus Hf Compositions and Methods for Cell Therapy
WO2019241758A1 (en) * 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof

Also Published As

Publication number Publication date
EP3850003A1 (en) 2021-07-21
TW202348622A (zh) 2023-12-16
CN112969710A (zh) 2021-06-15
KR20210058902A (ko) 2021-05-24
TW202023604A (zh) 2020-07-01
NZ774126A (en) 2023-05-26
AU2019338416A1 (en) 2021-04-29
JP2021535761A (ja) 2021-12-23
US20200181231A1 (en) 2020-06-11
US20230131056A1 (en) 2023-04-27
CA3109983A1 (en) 2020-03-19
US11498955B2 (en) 2022-11-15
TWI815964B (zh) 2023-09-21
WO2020056085A1 (en) 2020-03-19

Similar Documents

Publication Publication Date Title
SG11202011743SA (en) Fusion proteins comprising progranulin
SG11202104136YA (en) Heterodimeric fc-fused proteins
IL265657A (en) Immunomodulatory fusion proteins
EP3880814A4 (en) FUSION PROTEIN
IL254965A0 (en) fusion proteins
SG11202101904UA (en) Spd-1 variant - fc fusion proteins
GB201509413D0 (en) Fusion protein
ZA202003845B (en) Fusion proteins
ZA201906235B (en) Csf1r-based chimeric proteins
GB201504691D0 (en) Fusion protein
DK3737402T3 (en) Modificeret protein
IL290675A (en) Medical protein concentrates
ZA202102533B (en) Fusion protein
IL273626A (en) Immunomodulatory fusion proteins
ZA202007491B (en) Stable fusion protein formulation
IL273271A (en) A fusion protein containing a residue of FGF-18
SG11202000775SA (en) Fusion tags for recombinant protein expression
IL281088A (en) FLT3L - based chimeric proteins
ZA201801394B (en) Fusion protein
IL268170A (en) vsig8-based chimeric proteins
GB201810052D0 (en) Polypeptide
GB201913804D0 (en) Fusion polypeptides
GB201712792D0 (en) Fusion protein
EP3649159C0 (en) FUSION PROTEIN
GB201602850D0 (en) Fusion proteins